ABSTRACT
Objective: To evaluate the effectiveness of intravitreal Bevacizumab in decreasing central macular thickness in branch retinal vein occlusion [BRVO] related macular edema. Study Design: Quasi experimental study. Place and Duration of Study: Armed Forces Institute of Ophthalmology [AFIO], Rawalpindi, Pakistan, from March to August 2017
Methodology: Intravitreal Bevacizumab [1.25 mg/0.05 ml] was given in inferotemporal quadrant under aseptic conditions on monthly basis for consective three months. Post-injection, all the patients were followed up on monthly basis for consecutive three months. CMT [in microm] was measured by using OCT at baseline and after intravitreal Bevacizumab injections at one month, two months, and finally at three months
Results: Forty eyes of forty patients were included in the study. There were 25 [62.5%] male patients and 15 [37.5%] female patients. Baseline mean CMT +/-SD was 358 +/-36 microm before IVB injection. Mean CMT was 252 +/-12 microm at 3 months [after three IVB injections]. At three months, mean percentage decrease in CMT was 29.60%
Conclusion: Intravitreal Bevacizumab is effective and results in decrease in central macular thickness to normal or nearnormal levels in branch retinal vein occlusion [BRVO] related macular edema
ABSTRACT
Objective: To evaluate the effectiveness of combined Intravitreal triamcinolone acetonide [IVTA] and Intravitreal Bevacizumab [IVB] for treatment of refractory diabetic macular edema
Study Design: Quasi-experimental study
Place and Duration of Study: Armed Forces Institute of Ophthalmology [AFIO], Rawalpindi, from January to December 2017
Methodology: Pseudophakic diabetic patients with macular edema refractory to prior treatment were included. Patients having best corrected visual acuity [BCVA] better than 20/40 [6/12] or worse than 20/200[6/60] or the central subfield thickness [CSFT] less than 300 um on spectral domain optical coherence tomography [OCT] were excluded. Effectiveness of treatment was compared in terms of change in BCVA and CSFT on OCT. Intravitreal injection of 2 mg IVTA and 1.25 mg of IVB was given. IVB was repeated on monthly basis in next two months. Follow-up was done after one week of first injection and then monthly for next three months
Results: Fifty eyes of 42 patients were studied. Mean age of the patients was 62.4 years +/- 7.13. Male to female ratio was 2:1. Mean pre op LogMAR visual acuity was 0.708 +/- 0.12 and CSFT was 439.10 +/- 54.64 um. Mean postoperative LogMAR visual acuity was 0.586 +/- 0.13 um and mean post op CSFT was 382.80 +/- 56.12. There is statistically significant difference in improvement of LogMAR BCVA and decrease in CSFT after treatment. [p<0.001, paired t-test]
Conclusion: Eyes with refractory macular edema showed improvement of visual acuity and reduction of CSFT at three months when treated with combined IVTA and IVB
ABSTRACT
Objective: To evaluate the effectiveness of intravitreal Bevacizumab in decreasing central macular thickness in branch retinal vein occlusion [BRVO] related macular edema
Study Design: Quasi experimental study
Place and Duration of Study: Armed Forces Institute of Ophthalmology [AFIO], Rawalpindi, Pakistan, from March to August 2017
Methodology: Intravitreal Bevacizumab [1.25 mg/0.05 ml] was given in inferotemporal quadrant under aseptic conditions on monthly basis for consective three months. Post-injection, all the patients were followed up on monthly basis for consecutive three months. CMT [in ìm] was measured by using OCT at baseline and after intravitreal Bevacizumab injections at one month, two months, and finally at three months
Results: Forty eyes of forty patients were included in the study. There were 25 [62.5%] male patients and 15 [37.5%] female patients. Baseline mean CMT +/-SD was 358 +/-36 Mum before IVB injection. Mean CMT was 252 +/-12 Mum at 3 months [after three IVB injections]. At three months, mean percentage decrease in CMT was 29.60%
Conclusion: Intravitreal Bevacizumab is effective and results in decrease in central macular thickness to normal or nearnormal levels in branch retinal vein occlusion [BRVO] related macular edema